Currie, J.-C.; Demeule, M.; Charfi, C.; Zgheib, A.; Larocque, A.; Danalache, B.A.; Ouanouki, A.; Béliveau, R.; Marsolais, C.; Annabi, B.
The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers. Cancers 2022, 14, 1877.
https://doi.org/10.3390/cancers14081877
AMA Style
Currie J-C, Demeule M, Charfi C, Zgheib A, Larocque A, Danalache BA, Ouanouki A, Béliveau R, Marsolais C, Annabi B.
The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers. Cancers. 2022; 14(8):1877.
https://doi.org/10.3390/cancers14081877
Chicago/Turabian Style
Currie, Jean-Christophe, Michel Demeule, Cyndia Charfi, Alain Zgheib, Alain Larocque, Bogdan Alexandru Danalache, Amira Ouanouki, Richard Béliveau, Christian Marsolais, and Borhane Annabi.
2022. "The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers" Cancers 14, no. 8: 1877.
https://doi.org/10.3390/cancers14081877
APA Style
Currie, J.-C., Demeule, M., Charfi, C., Zgheib, A., Larocque, A., Danalache, B. A., Ouanouki, A., Béliveau, R., Marsolais, C., & Annabi, B.
(2022). The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers. Cancers, 14(8), 1877.
https://doi.org/10.3390/cancers14081877
